Asset
OTLERTUZUMAB
Aptevo Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01317901 | phase1 | completed | 2011-05-01 | 2013-04-01 | Aptevo Therapeutics | A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma |
| NCT00614042 | phase1 | completed | 2008-01-01 | 2011-12-01 | Aptevo Therapeutics | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma |
| NCT01644253 | phase1 | terminated | 2012-09-01 | 2020-02-24 | Aptevo Therapeutics | Phase 1b Safety and Efficacy Study of TRU-016 |
| NCT01188681 | phase1_2 | completed | 2010-09-01 | 2014-12-01 | Aptevo Therapeutics | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia |
FDA applications (0)
This company has no applications containing this asset.